AbbVie (ABBV) Stock Forecast for 2024–2028. Sell or Buy?

The chart below shows the historical price of AbbVie stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the AbbVie stock price can be found in the table below.

Long-term forecasts by years.

Under the leadership of Richard Gonzalez, AbbVie’s management has raised their financial projection for 2023, particularly in regards to the adjusted diluted EPS. Initially anticipated to be in the range of $10.86–$11.06, it has been revised to a ballpark estimate of $11.19–$11.23.

Additionally, the company increased its quarterly cash dividend by 4.7%, raising it to a significant amount of $1.55.

Its primary products, Skyrizi (risankizumab) and Rinvoq (upadacitinib), continue to thrive with sales reaching an impressive $3.24 billion in Q3 of 2023 alone—a steep 55% surge compared to the earnings from the same period last year.

AbbVie’s strong Q3 financials have been instrumental in shifting our risk vs. reward sweet spot upwards—from $124 per share to around the $133–$134.5 range. Going forward, our stance remains at “hold” for AbbVie’s stock for approximately another year.

AbbVie, traded under ABBV on the NYSE and based in North Chicago, is one of the leading players in today’s global pharmaceutical industry. As we predicted earlier, since our last discussion on this subject matter, AbbVie’s share prices have seen further reduction. We attribute this upward revision from $124 per share to around $133–$134.5 primarily due to AbbVie’s healthy Q3 results.

Moreover, what strongly argues in favor of this revision is the company’s decision to raise its fiscal guidance for 2023’s adjusted diluted EPS—originally projected at $10.86–$11.06—now expected to fall within the range of $11.19–$11.23.

The company’s neuroscience division, in particular Qulipta (atogepant), put forth a strong performance that is largely responsible for this upward revision.

Approved for both episodic and chronic migraine prevention, the drug—dependent greatly on its anti-CGRP receptor mode of action and oral intake—saw an astounding 112.9% rise year-over-year in sales in Q3 2023, hitting $132 million.

AbbVie Inc. (NYSE:ABBV), an American drugmaker known for its innovative research and product development, recently announced a quarterly dividend of $1.48 per share on September 8. This tracks evenly with the company’s past dividend distribution and continues to position it as one of the brightest stars in our constellation of ‘dividend kings’. With a history of increasing dividends consistently over the last half-century, it boasts an attractively steady return for investors. As of September 23, AbbVie stock had a dividend yield of 3.88%.

In more recent news, as Q2 2023 draws to a close, investment management coming out of hedge funds seems slightly less bullish – numbering at 74 according to Insider Monkey’s tracking – compared to the previous quarter’s count of 75. Despite this marginal drop, however, the value contained within these stakes can’t be ignored – totalling over a whopping $2.37 billion.

Official site of the company

AbbVie last paid dividends on 07/15/2024. The next scheduled payment will be on 08/15/2024. The amount of dividends is $6.06 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.